Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive...

Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma

ENHERTU followed by THP approved in China as the first and only HER2 directed ADC...

Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed...

Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer

DATROWAY Supplemental New Drug Application submitted in Japan for patients with metastatic triple negative breast...

First patient dosed for a Phase 1b/2 clinical trial of PD-L1 ADC HLX43 combination therapy...

Innovent dosed first participant in Phase 3 clinical study of IBI354 (novel HER2 ADC) for...